Trials / Completed
CompletedNCT00517049
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g)
A Phase II, Single-Arm, Open-Label Study of the Safety, Pharmacokinetics, and Efficacy of Multiple Doses of PRO95780 Administered Intravenously in Combination With Rituximab in Patients With Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This Phase II, single-arm, open-label, multicenter trial is designed to evaluate the safety, efficacy, and pharmacokinetics of PRO95780 when combined with rituximab in patients with follicular, CD20-positive B-cell NHL that has progressed following previous rituximab therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PRO95780 | Intravenous repeating dose |
| DRUG | rituximab | Intravenous repeating dose |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2007-08-16
- Last updated
- 2017-06-06
Source: ClinicalTrials.gov record NCT00517049. Inclusion in this directory is not an endorsement.